UNSPSC 51432807: Enalaprilat anhydrous

This classification denotes an ace inhibitor with the molecular formula C18H24N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q508Q118JM, chemically known as l-proline, 1-(n-(1-carboxy-3-phenylpropyl)-l-alanyl)-, (s)-, but more generally known as enalaprilat anhydrous, which bears US NIH Compound Identifier 5362033. European Medicines Agency schedules enalaprilat anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06515MIG.

Most nations, for tariff purposes, schedule enalaprilat anhydrous under HS 29339990. Enalaprilat anhydrous bears US NLM identifiers UMLS ID C0886809 and NCI Concept Code C76135. SMILES: C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2CCCCC2)C(=O)O.

UNSPSC 51432807 Enalaprilat anhydrous is a Commodity code that encompasses pharmaceutical products used in emergency medical services and acute care settings. State and local government procurement under this code centers on supply of injectable medications for advanced life support protocols, including specific formulations and concentrations required by fire rescue departments, emergency medical services, and hospital systems. The solicitations show demand for medications in bulk unit quantities with strict requirements for shelf life, expiration tracking, and compliance with OSHA hazard communication standards and federal accessibility documentation. Fire rescue departments and municipal health agencies are the primary issuing bodies, with purchases typically structured as annual term contracts with renewal and extension options. Vendors commonly must warrant product integrity for minimum periods (often 365 days) and manage logistics including delivery windows, expired-material replacement, and freight costs to the point of use.

The City of Tampa Fire Rescue in Hillsborough County, Florida represents recent activity in the code. In April 2026, the City of Tampa issued an IFB (Bid No. 26P00188) for Advanced Life Support Medications, posting April 24, 2026 with a response due April 8, 2026 — a compressed timeline indicating a replacement or urgent replenishment cycle. The solicitation called for four medication line items including 1,810 units of Epinephrine 1:10,000 injections, 1,020 units of Diltiazem 25mg vials, 370 units of Labetalol HCI 100mg vials, and 330 units of Adenosine 6mg vials, with an estimated contract value of $40,000.00. The award went to the lowest responsive, responsible bidder under a one-year term with two optional one-year renewals and up to three additional 30-day extensions. The City applied a Small Local Business Enterprise sheltered market designation with a 5 percent bid discount capped at $10,000, and required comprehensive VPAT accessibility documentation and OSHA Safety Data Sheets from all vendors.